Current Report Filing (8-k)
27 Mai 2021 - 10:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act Of 1934
Date of Report (Date of earliest event reported):
May 25, 2021
___________________________________________________________
ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as specified in its Charter)
___________________________________________________________
New York
|
1-10113
|
11-0853640
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices) (Zip code)
(847) 705-7709
(Registrant’s telephone number, including
area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common Stock, $0.01 par value per share
|
ACUR
|
OTCQB Market
|
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported, on May 25, 20121 we held
our Annual Meeting of Shareholders at which the shareholders voted for the adoption of our 2021 Restricted Stock Unit Award Plan (the
“Plan”). The material terms of the Plan are described under the captions “General”, “Administration”,
“RSU Plan Eligibility”, “Terms”, “Amendment and Termination of the RSU Plan” and “Adjustments
upon Changes in Capitalization or Merger” of Proposal 4 of our definitive proxy statement filed with the Securities and Exchange
Commission on April 12, 2021 (the "Proxy Statement"), which descriptions are incorporated by reference herein. The description
of the Plan in the Proxy Statement is qualified in its entirety by reference to the full text of the Plan, a copy of which is attached
as Exhibit 10.1.
Item 9.01 Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 27, 2021
|
ACURA PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Peter A. Clemens
|
|
|
Peter A. Clemens
|
|
|
Senior Vice President & Chief Financial Officer
|
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
Real-Time news about Acura Pharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Acura Pharmaceuticals, Inc